AbbVie (NYSE: ABBV) and Aliada Therapeutics announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing...
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing ...
Bristol Myers Squibb (NYSE: BMY) announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio...
Innovative Trials is the second fastest-growing, woman-powered UK company in the clinical research sector and in the top 200 overall, according to ...
JBI-802 is a first-in-class, orally administered, inhibitor of CoREST complex JBI-778 is a potential best-in-class, orally ad...
OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epine...
GC Biopharma announced that it has signed an agreement with Novelty Nobility, a biotech company specializing in the development of antibody-based therape...
The Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) conference taking place at the Walter E. Washington Convent...
Adona Medical, a Shifamed portfolio company that aims to deliver advanced solutions for heart failure, announced the successful first-in-human use of ...
Novartis presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with C3...
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced the company will present modeling data evaluati...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi will present positive data from the Phase 3 LIBERTY-CUPID Study C evaluating the inves...
Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD) annual con...
AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') announced a new discovery, co-development and license agreement to advance novel targets for ...
© 2025 Biopharma Boardroom. All Rights Reserved.
